Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic s Q2 Revenue Grows 15.5 Percent as R&D Spending, Losses Decline

NEW YORK, Aug. 12 (GenomeWeb News) - Transgenomic today reported a 15.5-percent decline in second-quarter revenue atop significantly reduced R&D spending and a wide reduction in net loss.


Total receipts for the three months ended June 30 fell to $7.6 million from $9 million year over year.


R&D spending in the quarter plummeted to $581,000 from $1.7 million in the year-ago period.


The decline in R&D spending together with an 18.6-percent reduction in selling, general, and administrative costs helped the company post a 93-percent drop in net loss. Total net losses in the second quarter fell to $998,000, or $.03 per share, from $15.1 million, or $.52 per share, year over year, Transgenomic said.


Buttressed by a restructuring completed in February, the earnings "reflect a renewed focus on our Biosystems business," CEO Collin D'Silva said in a statement.


He added that he expect the company to "achieve operating cash flow break even by year end, driven by expected acceleration in revenue growth in our Biosystems segment for the remainder of the fiscal year."


Transgenomic said it had around $1.7 million in cash, equivalents, and short-term investments as of June 30.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.